Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Paracetamol+caffeine 500mg/65mg soluble tablet |
Is a |
Product containing caffeine and paracetamol (medicinal product) |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Non-opioid analgesic (substance) |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Paracetamol |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Has manufactured dose form |
A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Phosphodiesterase inhibitor |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Caffeine |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Xanthine |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Has manufactured dose form |
Oral tablet |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Is a |
Product containing caffeine in oral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Is a |
Product containing paracetamol in oral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Has manufactured dose form |
Soluble tablet |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Has manufactured dose form |
Tablet for oral solution |
false |
Inferred relationship |
Some |
|
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
Is a |
TEMPORARY parent for CDs that are not updated |
false |
Inferred relationship |
Some |
|
|